Our Team

Mr. Smeeding is a founder of the Center for Pharmacoeconomic Studies at the University of Texas College Of Pharmacy. His research interests are in applied pharmacoeconomics, systems integration and managed care. Mr. Smeeding served as the executive director of the National Association of Specialty Pharmacy (NASP). He left that position to focus on the discovery work and management of Indication Biosciences. Over the past 43 years his practice orientation has been in hospital pharmacy, clinical services design, home infusion therapy, managed care services, disease management and specialty pharmacy. He is a skilled corporate pharmaceutical executive having developed and led five successful companies through initial funding to sale. Mr. Smeeding is a consultant to clients in a broad spectrum of pharmacy affairs, as well as pharmaceutical and medical device companies. Mr. Smeeding graduated with a pharmacy degree from the University of Buffalo and earned his MBA degree at the University of Texas. 

• Former executive Director of National Association of Specialty Pharmacies (NASP)
   
• Founder and 3rd President of the International Society of Pharmacoeconomics and Outcomes Research
   
• Past President of the Texas Society of Hospital Pharmacists
   
• Holds patents on the use of digital technology in prescription adjudication
   
• Has Authored over 50 articles in health value assessment topics and on the use of ECS
  Medicines
   

Mr. Sherwood has over twenty years of experience in healthcare, both in private practice and as a consultant. Mathew received his board certification as an optician from the American Board of Opticianry in 1998 and worked as an optician as well as a consultant in both practice management and optical laboratory solutions. As an optician, Mathew developed solutions for ophthalmic lens manufacturing and high-performance prescription applications. For most of the last decade Mathew has turned his focus to pharma, developing a variety of ECS-based medicines and has a deep understanding of the potential of ECS. Mathew focuses on product development, formulation, pre-clinical, CMC, and regulatory affairs. Mathew served as VP of Product Development for an early-stage drug company, and also worked as a consultant in specialty pharmacy helping to establish the National Association of Specialty Pharmacy, serving as Industry Liaison.
 

• Former Officer and Director for a publicly-traded pharmaceutical company with a valuation over $50 million
 

• Consulted with providers on therapies for patients in various disease states.

• Frequent guest speaker and ECS expert for pharmaceutical and financial conferences. 

- granted multiple patents on ECS pharmaceuticals

Harry Koppel serves as the Chief Financial Officer at Indication BioScience, bringing a wealth of financial expertise and strategic leadership to the organization. With a distinguished career in finance, Harry has demonstrated a strong commitment to driving fiscal excellence and supporting the growth of dynamic companies.

Prior to joining Indication BioScience, Harry held key financial roles at Barclay's London where he played a pivotal role in optimizing financial performance, managing capital structures, and executing successful financial strategies. His comprehensive understanding of the financial landscape, combined with a keen eye for opportunities, has contributed to the success and sustainability of the organizations he has served.

Harry is a seasoned professional known for his ability to navigate complex financial challenges and his dedication to aligning financial initiatives with overall business objectives. As CFO of Indication BioScience, he plays a crucial role in shaping the company's financial direction, ensuring sound fiscal management, and supporting the advancement of innovative solutions in the biotechnology sector.

With a commitment to excellence, strategic vision, and a proven track record in financial leadership, Harry Koppel is a valuable asset to the Indication BioScience team, contributing to the company's success in the dynamic and evolving field of biotechnology. 

Mr. Pechenik is a registered patent attorney with over a decade of experience obtaining, defending, and challenging some of the country’s most valuable and highest profile patents. Mr. Pechenik has represented numerous Fortune 500 companies on their patent matters, across the agricultural, chemical, pharmaceutical, biotech, and technology industries. His clients have included Pfizer, Roche, Sanofi- Aventis, Wyeth, DuPont, Pioneer Hi-Bred, Motorola, and Google. After working in the patent departments of the international law firms Kaye Scholer in New York and Quinn Emanuel in San Francisco, Mr. Pechenik founded Calyx Law. There, Mr. Pechenik works closely with businesses to design and implement their patent strategy. Mr. Pechenik graduated from New York University School of Law, and holds a Bachelors of Science from the University of California, San Diego, with majors in Biochemistry and Cell Biology, and Cognitive Neuroscience.
 

 30 + years in pharma for clinical development and medical affairs for global drug development and cardiovascular product launches.

Initially served as Associate Medical Affairs Director at Merck International for Mevacor launch , the first lipid lowering drug of its class 

Medical Consultant to Pfizer cardiovascular development team for cardiovascular endpoint committee liaison services in the phase 3 study of Lipitor 

Senior Medical Director at Esperion Therapeutics for the development of bempanoic acid FDA approved as the first in class lipid lowering drug with a unique safety profile to avoid skeletal muscle adverse side effects 

Previously academic appointment as the Medical Director at the Harvard Clinical Research Institute 

for cardiovascular drug and device development 

Member of the American Medical Association and former member of the Royal Society of Medicine UK since 1988